Moderna(MRNA) - 2023 Q2 - Earnings Call Presentation

Second Quarter 2023 Financial Results moderr l Financial figures in this presentation as of, and for the quarterly periods ended, June 30, 2023, and June 30, 2022, are unaudited. 2 2Q23 earnings call agenda R&D/Clinical Programs Stephen Hoge, M.D., President Financials Jamey Mock, CFO 3 2Q23 financial highlights Net income (loss): $(1.4) billion Reinvest in the business • $0.2 billion capital expenditures Return capital to shareholders 2Q 2023 Update| Business Review • Submitted updated COVID-19 vaccine to ...